DNA methyltransferase expression (DNMT1, DNMT3a and DNMT3b) as a potential biomarker for anti-VEGF diabetic macular edema response
- PMID: 37082811
- PMCID: PMC10590013
- DOI: 10.1177/11206721231171623
DNA methyltransferase expression (DNMT1, DNMT3a and DNMT3b) as a potential biomarker for anti-VEGF diabetic macular edema response
Abstract
Purpose: DNA methylation is involved in Diabetic Retinopathy progression showing a metabolic memory mechanism. However, the association of DNA methyltransferase with diabetic macular edema is still unknown. We aimed to describe the differences in DNA methyltransferase gene expression in patients with different diabetic macular edema responses.
Methods: A total of 27 diabetic patients, aged 59-90 years, were prospectively enrolled in this cross-sectional study. The participants were classified into control group (CG, n = 11), diabetic macular edema responders (rDME, n = 9) and non-responder diabetic macular edema (nrDME, n = 7) after anti-vascular endothelial growth factor (anti-VEGF) treatment. Only cases with a complete ophthalmological examination, digital 133° color fundus, and SD-OCT assessments were used. After RNA extraction and first-strand cDNA synthesis, quantitative real-time PCR was performed with specific primers on the CFX Connect™ Real-Time PCR Detection System to assess differential transcriptional expression patterns.
Results: The DNMT1 gene showed a positive correlation (r = 0.617; p = 0.043) with Best Corrected Visual Acuity (BCVA) in CG, a positive correlation (r = 0.917; p = 0.010) with HbA1c in nrDME and a negative correlation (r = -0.659; p = 0.049) with GCL-IPL thickness in rDME. DNMT3A gene showed a positive correlation (r = -0.890; p = 0.001) with Sub-foveal Choroidal thickness in rDME whereas DNMT3b gene showed a negative correlation (r = -0.815; p = 0.007) with HbA1c and RNFL (r = -0.664; p = 0.026) in CG.
Conclusions: Patients with similar metabolic profile risk factors showed associated DNA methyltransferase transcriptional expression patterns differences fitting with the anti-VEGF diabetic macular edema response. Further studies are needed to clarify if these results (1) reflect disease evolution, (2) translate the therapeutic impact, (3) or can help to predict the therapeutic resistance profile.
Keywords: DNA methylation; Diabetic retinopathy; diabetes mellitus; epigenetics; macular edema.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures

Similar articles
-
DNA Methyltransferase Expression (DNMT1, DNMT3a, and DNMT3b) as a Potential Biomarker in Age-Related Macular Degeneration.J Clin Med. 2025 Jan 16;14(2):559. doi: 10.3390/jcm14020559. J Clin Med. 2025. PMID: 39860565 Free PMC article.
-
Fundus microperimetry patterns of fixation in type 2 diabetic patients with diffuse macular edema.Retina. 2007 Jan;27(1):21-9. doi: 10.1097/01.iae.0000256658.71864.ca. Retina. 2007. PMID: 17218911
-
[Correlation of retinal sensitivity, visual acuity and central macular thickness in different types of diabetic macular edema].Zhonghua Yan Ke Za Zhi. 2013 Dec;49(12):1081-8. Zhonghua Yan Ke Za Zhi. 2013. PMID: 24499694 Chinese.
-
Treatment results of diabetic macular edema with different choroidal thickness with intravitreal anti vascular endothelial growth factor.BMC Ophthalmol. 2022 Dec 22;22(1):508. doi: 10.1186/s12886-022-02721-3. BMC Ophthalmol. 2022. PMID: 36550418 Free PMC article.
-
[Neurodegenerative biomarkers of the response to diabetic macular edema treatment].Vestn Oftalmol. 2020;136(4. Vyp. 2):201-206. doi: 10.17116/oftalma2020136042201. Vestn Oftalmol. 2020. PMID: 32880140 Russian.
Cited by
-
DNA Methyltransferase Expression (DNMT1, DNMT3a, and DNMT3b) as a Potential Biomarker in Age-Related Macular Degeneration.J Clin Med. 2025 Jan 16;14(2):559. doi: 10.3390/jcm14020559. J Clin Med. 2025. PMID: 39860565 Free PMC article.
-
Advances in the molecular signaling mechanisms of VEGF/VEGFR2 in fundus neovascularization disease (Review).Exp Ther Med. 2025 May 20;30(1):143. doi: 10.3892/etm.2025.12893. eCollection 2025 Jul. Exp Ther Med. 2025. PMID: 40496761 Free PMC article. Review.
-
Insights into the mechanisms of angiogenesis in hepatoblastoma.Front Cell Dev Biol. 2025 May 14;13:1535339. doi: 10.3389/fcell.2025.1535339. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40438141 Free PMC article. Review.
-
WNT-inhibitory factor 1-mediated glycolysis protects photoreceptor cells in diabetic retinopathy.J Transl Med. 2024 Mar 6;22(1):245. doi: 10.1186/s12967-024-05046-5. J Transl Med. 2024. PMID: 38448948 Free PMC article.
-
Epigenetic Alterations in Age-Related Macular Degeneration: Mechanisms and Implications.Int J Mol Sci. 2025 Aug 6;26(15):7601. doi: 10.3390/ijms26157601. Int J Mol Sci. 2025. PMID: 40806731 Free PMC article. Review.
References
-
- Forouzanfar MH, Afshin A, Alexander LT, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1659–1724. - PMC - PubMed
-
- Mishra M, Kowluru RA. DNA Methylation—a potential source of mitochondria DNA base mismatch in the development of diabetic retinopathy. Mol Neurobiol 2019; 56: 88–101. - PubMed
-
- Gonzalez VH, Campbell J, Holekamp NM, et al. Early and long-term responses to anti–vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 2016; 172: 72–79. - PubMed
LinkOut - more resources
Full Text Sources